Clinical & Translational Oncology-期刊论坛，投稿经验-MedSci.cn

[GetPortalCommentsPageByObjectIdResponse(id=1240305, encodeId=022a1240305ed, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：胃癌;生信;预后标志物 经验分享：8月9号投稿，22号被拒，期间一直是"Editor Assigned"状态，20号写了一份催稿信，不知道是这个原因，还是本身纯生信原因。被拒说不适合，建议转投，但是该杂志有统计和生信相关主编。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=35, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74665434563, createdName=ms2000000713462597, createdTime=Mon Aug 22 16:56:30 CST 2022, time=2022-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1224993, encodeId=5aab122499350, content=偏重的研究方向：乳腺癌;内分泌治疗 经验分享：三天了还在new submission，大概要多久啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=27, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=99c56511981, createdName=ms8000000784741196, createdTime=Tue Jun 07 16:45:07 CST 2022, time=2022-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1225234, encodeId=59e01225234bb, content=请问大家，投出去三个多月了，反复的“指派审稿人”“审稿重”什么意思呀？已经重复三次了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=29, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c5a35503965, createdName=ms1000001119710084, createdTime=Wed Jun 08 17:31:53 CST 2022, time=2022-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1204339, encodeId=6bb0120433935, content=请问下大家这个杂志格式要求很严格吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=31, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=44935423762, createdName=ms4000001175598795, createdTime=Sun Mar 20 14:01:28 CST 2022, time=2022-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1101376, encodeId=cba911013e68e, content=模式图一般放在讨论中展示还是放在结果部分？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=47, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/3a52d3952dde49019f1e000bb5c41d1c/0a0eb7959bb14fcd87745f869bee3c33.jpg, createdBy=46f32239729, createdName=Mia, createdTime=Wed Dec 29 14:52:51 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1101375, encodeId=a3c311013e5eb, content=讨论中第一段一定要撰写文章的总括么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=47, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ff65466529, createdName=ms6000000264964247, createdTime=Tue Dec 28 14:52:51 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1071356, encodeId=77ad10e135610, content=投了之后说给介绍期刊转投，1周了没有消息，请问有遇到这种情况的同学吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=45, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=02925649921, createdName=ms9000001676514510, createdTime=Thu Nov 18 11:02:32 CST 2021, time=2021-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=522379, encodeId=c5d95223e918, content=刚投一篇回顾性临床研究文章，希望能被接收，祈祷！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=322, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2acf1721622, createdName=1dec8fb5m12(暂无匿称), createdTime=Sat May 14 11:06:00 CST 2016, time=2016-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=907209, encodeId=979390e2098c, content=攒人品，纯生信，一天秒拒, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=114, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0cfd2480964, createdName=1245a12em04(暂无昵称), createdTime=Sat Dec 12 00:13:53 CST 2020, time=2020-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1008310, encodeId=9cd410083104d, content=偏重的研究方向：肿瘤 经验分享：一天秒拒无理由, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=58, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f9015376971, createdName=ms9000000537367142, createdTime=Mon Aug 16 13:16:44 CST 2021, time=2021-08-16, status=1, ipAttribution=)]

2022-08-22 ms2000000713462597

审稿速度:1.0 | 投稿命中率:25.0
偏重的研究方向：胃癌;生信;预后标志物
经验分享：8月9号投稿，22号被拒，期间一直是"Editor Assigned"状态，20号写了一份催稿信，不知道是这个原因，还是本身纯生信原因。被拒说不适合，建议转投，但是该杂志有统计和生信相关主编。

35 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=1240305, encodeId=022a1240305ed, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：胃癌;生信;预后标志物 经验分享：8月9号投稿，22号被拒，期间一直是"Editor Assigned"状态，20号写了一份催稿信，不知道是这个原因，还是本身纯生信原因。被拒说不适合，建议转投，但是该杂志有统计和生信相关主编。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=35, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74665434563, createdName=ms2000000713462597, createdTime=Mon Aug 22 16:56:30 CST 2022, time=2022-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1224993, encodeId=5aab122499350, content=偏重的研究方向：乳腺癌;内分泌治疗 经验分享：三天了还在new submission，大概要多久啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=27, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=99c56511981, createdName=ms8000000784741196, createdTime=Tue Jun 07 16:45:07 CST 2022, time=2022-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1225234, encodeId=59e01225234bb, content=请问大家，投出去三个多月了，反复的“指派审稿人”“审稿重”什么意思呀？已经重复三次了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=29, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c5a35503965, createdName=ms1000001119710084, createdTime=Wed Jun 08 17:31:53 CST 2022, time=2022-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1204339, encodeId=6bb0120433935, content=请问下大家这个杂志格式要求很严格吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=31, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=44935423762, createdName=ms4000001175598795, createdTime=Sun Mar 20 14:01:28 CST 2022, time=2022-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1101376, encodeId=cba911013e68e, content=模式图一般放在讨论中展示还是放在结果部分？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=47, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/3a52d3952dde49019f1e000bb5c41d1c/0a0eb7959bb14fcd87745f869bee3c33.jpg, createdBy=46f32239729, createdName=Mia, createdTime=Wed Dec 29 14:52:51 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1101375, encodeId=a3c311013e5eb, content=讨论中第一段一定要撰写文章的总括么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=47, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ff65466529, createdName=ms6000000264964247, createdTime=Tue Dec 28 14:52:51 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1071356, encodeId=77ad10e135610, content=投了之后说给介绍期刊转投，1周了没有消息，请问有遇到这种情况的同学吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=45, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=02925649921, createdName=ms9000001676514510, createdTime=Thu Nov 18 11:02:32 CST 2021, time=2021-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=522379, encodeId=c5d95223e918, content=刚投一篇回顾性临床研究文章，希望能被接收，祈祷！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=322, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2acf1721622, createdName=1dec8fb5m12(暂无匿称), createdTime=Sat May 14 11:06:00 CST 2016, time=2016-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=907209, encodeId=979390e2098c, content=攒人品，纯生信，一天秒拒, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=114, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0cfd2480964, createdName=1245a12em04(暂无昵称), createdTime=Sat Dec 12 00:13:53 CST 2020, time=2020-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1008310, encodeId=9cd410083104d, content=偏重的研究方向：肿瘤 经验分享：一天秒拒无理由, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=58, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f9015376971, createdName=ms9000000537367142, createdTime=Mon Aug 16 13:16:44 CST 2021, time=2021-08-16, status=1, ipAttribution=)]

2022-06-07 ms8000000784741196

偏重的研究方向：乳腺癌;内分泌治疗
经验分享：三天了还在new submission，大概要多久啊

27 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=1240305, encodeId=022a1240305ed, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：胃癌;生信;预后标志物 经验分享：8月9号投稿，22号被拒，期间一直是"Editor Assigned"状态，20号写了一份催稿信，不知道是这个原因，还是本身纯生信原因。被拒说不适合，建议转投，但是该杂志有统计和生信相关主编。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=35, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74665434563, createdName=ms2000000713462597, createdTime=Mon Aug 22 16:56:30 CST 2022, time=2022-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1224993, encodeId=5aab122499350, content=偏重的研究方向：乳腺癌;内分泌治疗 经验分享：三天了还在new submission，大概要多久啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=27, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=99c56511981, createdName=ms8000000784741196, createdTime=Tue Jun 07 16:45:07 CST 2022, time=2022-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1225234, encodeId=59e01225234bb, content=请问大家，投出去三个多月了，反复的“指派审稿人”“审稿重”什么意思呀？已经重复三次了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=29, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c5a35503965, createdName=ms1000001119710084, createdTime=Wed Jun 08 17:31:53 CST 2022, time=2022-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1204339, encodeId=6bb0120433935, content=请问下大家这个杂志格式要求很严格吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=31, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=44935423762, createdName=ms4000001175598795, createdTime=Sun Mar 20 14:01:28 CST 2022, time=2022-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1101376, encodeId=cba911013e68e, content=模式图一般放在讨论中展示还是放在结果部分？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=47, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/3a52d3952dde49019f1e000bb5c41d1c/0a0eb7959bb14fcd87745f869bee3c33.jpg, createdBy=46f32239729, createdName=Mia, createdTime=Wed Dec 29 14:52:51 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1101375, encodeId=a3c311013e5eb, content=讨论中第一段一定要撰写文章的总括么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=47, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ff65466529, createdName=ms6000000264964247, createdTime=Tue Dec 28 14:52:51 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1071356, encodeId=77ad10e135610, content=投了之后说给介绍期刊转投，1周了没有消息，请问有遇到这种情况的同学吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=45, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=02925649921, createdName=ms9000001676514510, createdTime=Thu Nov 18 11:02:32 CST 2021, time=2021-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=522379, encodeId=c5d95223e918, content=刚投一篇回顾性临床研究文章，希望能被接收，祈祷！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=322, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2acf1721622, createdName=1dec8fb5m12(暂无匿称), createdTime=Sat May 14 11:06:00 CST 2016, time=2016-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=907209, encodeId=979390e2098c, content=攒人品，纯生信，一天秒拒, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=114, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0cfd2480964, createdName=1245a12em04(暂无昵称), createdTime=Sat Dec 12 00:13:53 CST 2020, time=2020-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1008310, encodeId=9cd410083104d, content=偏重的研究方向：肿瘤 经验分享：一天秒拒无理由, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=58, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f9015376971, createdName=ms9000000537367142, createdTime=Mon Aug 16 13:16:44 CST 2021, time=2021-08-16, status=1, ipAttribution=)]

2022-06-08 ms1000001119710084

请问大家，投出去三个多月了，反复的“指派审稿人”“审稿重”什么意思呀？已经重复三次了

29 2

展开2条回复

[GetPortalCommentsPageByObjectIdResponse(id=1240305, encodeId=022a1240305ed, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：胃癌;生信;预后标志物 经验分享：8月9号投稿，22号被拒，期间一直是"Editor Assigned"状态，20号写了一份催稿信，不知道是这个原因，还是本身纯生信原因。被拒说不适合，建议转投，但是该杂志有统计和生信相关主编。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=35, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74665434563, createdName=ms2000000713462597, createdTime=Mon Aug 22 16:56:30 CST 2022, time=2022-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1224993, encodeId=5aab122499350, content=偏重的研究方向：乳腺癌;内分泌治疗 经验分享：三天了还在new submission，大概要多久啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=27, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=99c56511981, createdName=ms8000000784741196, createdTime=Tue Jun 07 16:45:07 CST 2022, time=2022-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1225234, encodeId=59e01225234bb, content=请问大家，投出去三个多月了，反复的“指派审稿人”“审稿重”什么意思呀？已经重复三次了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=29, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c5a35503965, createdName=ms1000001119710084, createdTime=Wed Jun 08 17:31:53 CST 2022, time=2022-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1204339, encodeId=6bb0120433935, content=请问下大家这个杂志格式要求很严格吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=31, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=44935423762, createdName=ms4000001175598795, createdTime=Sun Mar 20 14:01:28 CST 2022, time=2022-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1101376, encodeId=cba911013e68e, content=模式图一般放在讨论中展示还是放在结果部分？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=47, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/3a52d3952dde49019f1e000bb5c41d1c/0a0eb7959bb14fcd87745f869bee3c33.jpg, createdBy=46f32239729, createdName=Mia, createdTime=Wed Dec 29 14:52:51 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1101375, encodeId=a3c311013e5eb, content=讨论中第一段一定要撰写文章的总括么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=47, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ff65466529, createdName=ms6000000264964247, createdTime=Tue Dec 28 14:52:51 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1071356, encodeId=77ad10e135610, content=投了之后说给介绍期刊转投，1周了没有消息，请问有遇到这种情况的同学吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=45, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=02925649921, createdName=ms9000001676514510, createdTime=Thu Nov 18 11:02:32 CST 2021, time=2021-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=522379, encodeId=c5d95223e918, content=刚投一篇回顾性临床研究文章，希望能被接收，祈祷！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=322, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2acf1721622, createdName=1dec8fb5m12(暂无匿称), createdTime=Sat May 14 11:06:00 CST 2016, time=2016-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=907209, encodeId=979390e2098c, content=攒人品，纯生信，一天秒拒, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=114, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0cfd2480964, createdName=1245a12em04(暂无昵称), createdTime=Sat Dec 12 00:13:53 CST 2020, time=2020-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1008310, encodeId=9cd410083104d, content=偏重的研究方向：肿瘤 经验分享：一天秒拒无理由, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=58, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f9015376971, createdName=ms9000000537367142, createdTime=Mon Aug 16 13:16:44 CST 2021, time=2021-08-16, status=1, ipAttribution=)]

2022-03-20 ms4000001175598795

请问下大家这个杂志格式要求很严格吗

31 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=1240305, encodeId=022a1240305ed, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：胃癌;生信;预后标志物 经验分享：8月9号投稿，22号被拒，期间一直是"Editor Assigned"状态，20号写了一份催稿信，不知道是这个原因，还是本身纯生信原因。被拒说不适合，建议转投，但是该杂志有统计和生信相关主编。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=35, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74665434563, createdName=ms2000000713462597, createdTime=Mon Aug 22 16:56:30 CST 2022, time=2022-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1224993, encodeId=5aab122499350, content=偏重的研究方向：乳腺癌;内分泌治疗 经验分享：三天了还在new submission，大概要多久啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=27, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=99c56511981, createdName=ms8000000784741196, createdTime=Tue Jun 07 16:45:07 CST 2022, time=2022-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1225234, encodeId=59e01225234bb, content=请问大家，投出去三个多月了，反复的“指派审稿人”“审稿重”什么意思呀？已经重复三次了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=29, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c5a35503965, createdName=ms1000001119710084, createdTime=Wed Jun 08 17:31:53 CST 2022, time=2022-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1204339, encodeId=6bb0120433935, content=请问下大家这个杂志格式要求很严格吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=31, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=44935423762, createdName=ms4000001175598795, createdTime=Sun Mar 20 14:01:28 CST 2022, time=2022-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1101376, encodeId=cba911013e68e, content=模式图一般放在讨论中展示还是放在结果部分？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=47, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/3a52d3952dde49019f1e000bb5c41d1c/0a0eb7959bb14fcd87745f869bee3c33.jpg, createdBy=46f32239729, createdName=Mia, createdTime=Wed Dec 29 14:52:51 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1101375, encodeId=a3c311013e5eb, content=讨论中第一段一定要撰写文章的总括么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=47, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ff65466529, createdName=ms6000000264964247, createdTime=Tue Dec 28 14:52:51 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1071356, encodeId=77ad10e135610, content=投了之后说给介绍期刊转投，1周了没有消息，请问有遇到这种情况的同学吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=45, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=02925649921, createdName=ms9000001676514510, createdTime=Thu Nov 18 11:02:32 CST 2021, time=2021-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=522379, encodeId=c5d95223e918, content=刚投一篇回顾性临床研究文章，希望能被接收，祈祷！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=322, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2acf1721622, createdName=1dec8fb5m12(暂无匿称), createdTime=Sat May 14 11:06:00 CST 2016, time=2016-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=907209, encodeId=979390e2098c, content=攒人品，纯生信，一天秒拒, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=114, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0cfd2480964, createdName=1245a12em04(暂无昵称), createdTime=Sat Dec 12 00:13:53 CST 2020, time=2020-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1008310, encodeId=9cd410083104d, content=偏重的研究方向：肿瘤 经验分享：一天秒拒无理由, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=58, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f9015376971, createdName=ms9000000537367142, createdTime=Mon Aug 16 13:16:44 CST 2021, time=2021-08-16, status=1, ipAttribution=)]

2021-12-29 Mia

模式图一般放在讨论中展示还是放在结果部分？

47 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=1240305, encodeId=022a1240305ed, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：胃癌;生信;预后标志物 经验分享：8月9号投稿，22号被拒，期间一直是"Editor Assigned"状态，20号写了一份催稿信，不知道是这个原因，还是本身纯生信原因。被拒说不适合，建议转投，但是该杂志有统计和生信相关主编。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=35, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74665434563, createdName=ms2000000713462597, createdTime=Mon Aug 22 16:56:30 CST 2022, time=2022-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1224993, encodeId=5aab122499350, content=偏重的研究方向：乳腺癌;内分泌治疗 经验分享：三天了还在new submission，大概要多久啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=27, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=99c56511981, createdName=ms8000000784741196, createdTime=Tue Jun 07 16:45:07 CST 2022, time=2022-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1225234, encodeId=59e01225234bb, content=请问大家，投出去三个多月了，反复的“指派审稿人”“审稿重”什么意思呀？已经重复三次了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=29, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c5a35503965, createdName=ms1000001119710084, createdTime=Wed Jun 08 17:31:53 CST 2022, time=2022-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1204339, encodeId=6bb0120433935, content=请问下大家这个杂志格式要求很严格吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=31, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=44935423762, createdName=ms4000001175598795, createdTime=Sun Mar 20 14:01:28 CST 2022, time=2022-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1101376, encodeId=cba911013e68e, content=模式图一般放在讨论中展示还是放在结果部分？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=47, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/3a52d3952dde49019f1e000bb5c41d1c/0a0eb7959bb14fcd87745f869bee3c33.jpg, createdBy=46f32239729, createdName=Mia, createdTime=Wed Dec 29 14:52:51 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1101375, encodeId=a3c311013e5eb, content=讨论中第一段一定要撰写文章的总括么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=47, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ff65466529, createdName=ms6000000264964247, createdTime=Tue Dec 28 14:52:51 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1071356, encodeId=77ad10e135610, content=投了之后说给介绍期刊转投，1周了没有消息，请问有遇到这种情况的同学吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=45, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=02925649921, createdName=ms9000001676514510, createdTime=Thu Nov 18 11:02:32 CST 2021, time=2021-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=522379, encodeId=c5d95223e918, content=刚投一篇回顾性临床研究文章，希望能被接收，祈祷！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=322, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2acf1721622, createdName=1dec8fb5m12(暂无匿称), createdTime=Sat May 14 11:06:00 CST 2016, time=2016-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=907209, encodeId=979390e2098c, content=攒人品，纯生信，一天秒拒, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=114, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0cfd2480964, createdName=1245a12em04(暂无昵称), createdTime=Sat Dec 12 00:13:53 CST 2020, time=2020-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1008310, encodeId=9cd410083104d, content=偏重的研究方向：肿瘤 经验分享：一天秒拒无理由, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=58, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f9015376971, createdName=ms9000000537367142, createdTime=Mon Aug 16 13:16:44 CST 2021, time=2021-08-16, status=1, ipAttribution=)]

2021-12-28 ms6000000264964247

讨论中第一段一定要撰写文章的总括么？

47 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=1240305, encodeId=022a1240305ed, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：胃癌;生信;预后标志物 经验分享：8月9号投稿，22号被拒，期间一直是"Editor Assigned"状态，20号写了一份催稿信，不知道是这个原因，还是本身纯生信原因。被拒说不适合，建议转投，但是该杂志有统计和生信相关主编。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=35, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74665434563, createdName=ms2000000713462597, createdTime=Mon Aug 22 16:56:30 CST 2022, time=2022-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1224993, encodeId=5aab122499350, content=偏重的研究方向：乳腺癌;内分泌治疗 经验分享：三天了还在new submission，大概要多久啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=27, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=99c56511981, createdName=ms8000000784741196, createdTime=Tue Jun 07 16:45:07 CST 2022, time=2022-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1225234, encodeId=59e01225234bb, content=请问大家，投出去三个多月了，反复的“指派审稿人”“审稿重”什么意思呀？已经重复三次了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=29, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c5a35503965, createdName=ms1000001119710084, createdTime=Wed Jun 08 17:31:53 CST 2022, time=2022-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1204339, encodeId=6bb0120433935, content=请问下大家这个杂志格式要求很严格吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=31, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=44935423762, createdName=ms4000001175598795, createdTime=Sun Mar 20 14:01:28 CST 2022, time=2022-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1101376, encodeId=cba911013e68e, content=模式图一般放在讨论中展示还是放在结果部分？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=47, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/3a52d3952dde49019f1e000bb5c41d1c/0a0eb7959bb14fcd87745f869bee3c33.jpg, createdBy=46f32239729, createdName=Mia, createdTime=Wed Dec 29 14:52:51 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1101375, encodeId=a3c311013e5eb, content=讨论中第一段一定要撰写文章的总括么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=47, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ff65466529, createdName=ms6000000264964247, createdTime=Tue Dec 28 14:52:51 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1071356, encodeId=77ad10e135610, content=投了之后说给介绍期刊转投，1周了没有消息，请问有遇到这种情况的同学吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=45, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=02925649921, createdName=ms9000001676514510, createdTime=Thu Nov 18 11:02:32 CST 2021, time=2021-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=522379, encodeId=c5d95223e918, content=刚投一篇回顾性临床研究文章，希望能被接收，祈祷！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=322, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2acf1721622, createdName=1dec8fb5m12(暂无匿称), createdTime=Sat May 14 11:06:00 CST 2016, time=2016-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=907209, encodeId=979390e2098c, content=攒人品，纯生信，一天秒拒, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=114, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0cfd2480964, createdName=1245a12em04(暂无昵称), createdTime=Sat Dec 12 00:13:53 CST 2020, time=2020-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1008310, encodeId=9cd410083104d, content=偏重的研究方向：肿瘤 经验分享：一天秒拒无理由, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=58, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f9015376971, createdName=ms9000000537367142, createdTime=Mon Aug 16 13:16:44 CST 2021, time=2021-08-16, status=1, ipAttribution=)]

2021-11-18 ms9000001676514510

投了之后说给介绍期刊转投，1周了没有消息，请问有遇到这种情况的同学吗？

45 2

展开2条回复

[GetPortalCommentsPageByObjectIdResponse(id=1240305, encodeId=022a1240305ed, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：胃癌;生信;预后标志物 经验分享：8月9号投稿，22号被拒，期间一直是"Editor Assigned"状态，20号写了一份催稿信，不知道是这个原因，还是本身纯生信原因。被拒说不适合，建议转投，但是该杂志有统计和生信相关主编。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=35, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74665434563, createdName=ms2000000713462597, createdTime=Mon Aug 22 16:56:30 CST 2022, time=2022-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1224993, encodeId=5aab122499350, content=偏重的研究方向：乳腺癌;内分泌治疗 经验分享：三天了还在new submission，大概要多久啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=27, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=99c56511981, createdName=ms8000000784741196, createdTime=Tue Jun 07 16:45:07 CST 2022, time=2022-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1225234, encodeId=59e01225234bb, content=请问大家，投出去三个多月了，反复的“指派审稿人”“审稿重”什么意思呀？已经重复三次了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=29, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c5a35503965, createdName=ms1000001119710084, createdTime=Wed Jun 08 17:31:53 CST 2022, time=2022-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1204339, encodeId=6bb0120433935, content=请问下大家这个杂志格式要求很严格吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=31, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=44935423762, createdName=ms4000001175598795, createdTime=Sun Mar 20 14:01:28 CST 2022, time=2022-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1101376, encodeId=cba911013e68e, content=模式图一般放在讨论中展示还是放在结果部分？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=47, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/3a52d3952dde49019f1e000bb5c41d1c/0a0eb7959bb14fcd87745f869bee3c33.jpg, createdBy=46f32239729, createdName=Mia, createdTime=Wed Dec 29 14:52:51 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1101375, encodeId=a3c311013e5eb, content=讨论中第一段一定要撰写文章的总括么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=47, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ff65466529, createdName=ms6000000264964247, createdTime=Tue Dec 28 14:52:51 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1071356, encodeId=77ad10e135610, content=投了之后说给介绍期刊转投，1周了没有消息，请问有遇到这种情况的同学吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=45, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=02925649921, createdName=ms9000001676514510, createdTime=Thu Nov 18 11:02:32 CST 2021, time=2021-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=522379, encodeId=c5d95223e918, content=刚投一篇回顾性临床研究文章，希望能被接收，祈祷！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=322, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2acf1721622, createdName=1dec8fb5m12(暂无匿称), createdTime=Sat May 14 11:06:00 CST 2016, time=2016-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=907209, encodeId=979390e2098c, content=攒人品，纯生信，一天秒拒, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=114, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0cfd2480964, createdName=1245a12em04(暂无昵称), createdTime=Sat Dec 12 00:13:53 CST 2020, time=2020-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1008310, encodeId=9cd410083104d, content=偏重的研究方向：肿瘤 经验分享：一天秒拒无理由, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=58, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f9015376971, createdName=ms9000000537367142, createdTime=Mon Aug 16 13:16:44 CST 2021, time=2021-08-16, status=1, ipAttribution=)]

2016-05-14 1dec8fb5m12(暂无匿称)

刚投一篇回顾性临床研究文章，希望能被接收，祈祷！

322 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=1240305, encodeId=022a1240305ed, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：胃癌;生信;预后标志物 经验分享：8月9号投稿，22号被拒，期间一直是"Editor Assigned"状态，20号写了一份催稿信，不知道是这个原因，还是本身纯生信原因。被拒说不适合，建议转投，但是该杂志有统计和生信相关主编。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=35, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74665434563, createdName=ms2000000713462597, createdTime=Mon Aug 22 16:56:30 CST 2022, time=2022-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1224993, encodeId=5aab122499350, content=偏重的研究方向：乳腺癌;内分泌治疗 经验分享：三天了还在new submission，大概要多久啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=27, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=99c56511981, createdName=ms8000000784741196, createdTime=Tue Jun 07 16:45:07 CST 2022, time=2022-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1225234, encodeId=59e01225234bb, content=请问大家，投出去三个多月了，反复的“指派审稿人”“审稿重”什么意思呀？已经重复三次了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=29, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c5a35503965, createdName=ms1000001119710084, createdTime=Wed Jun 08 17:31:53 CST 2022, time=2022-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1204339, encodeId=6bb0120433935, content=请问下大家这个杂志格式要求很严格吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=31, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=44935423762, createdName=ms4000001175598795, createdTime=Sun Mar 20 14:01:28 CST 2022, time=2022-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1101376, encodeId=cba911013e68e, content=模式图一般放在讨论中展示还是放在结果部分？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=47, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/3a52d3952dde49019f1e000bb5c41d1c/0a0eb7959bb14fcd87745f869bee3c33.jpg, createdBy=46f32239729, createdName=Mia, createdTime=Wed Dec 29 14:52:51 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1101375, encodeId=a3c311013e5eb, content=讨论中第一段一定要撰写文章的总括么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=47, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ff65466529, createdName=ms6000000264964247, createdTime=Tue Dec 28 14:52:51 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1071356, encodeId=77ad10e135610, content=投了之后说给介绍期刊转投，1周了没有消息，请问有遇到这种情况的同学吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=45, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=02925649921, createdName=ms9000001676514510, createdTime=Thu Nov 18 11:02:32 CST 2021, time=2021-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=522379, encodeId=c5d95223e918, content=刚投一篇回顾性临床研究文章，希望能被接收，祈祷！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=322, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2acf1721622, createdName=1dec8fb5m12(暂无匿称), createdTime=Sat May 14 11:06:00 CST 2016, time=2016-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=907209, encodeId=979390e2098c, content=攒人品，纯生信，一天秒拒, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=114, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0cfd2480964, createdName=1245a12em04(暂无昵称), createdTime=Sat Dec 12 00:13:53 CST 2020, time=2020-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1008310, encodeId=9cd410083104d, content=偏重的研究方向：肿瘤 经验分享：一天秒拒无理由, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=58, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f9015376971, createdName=ms9000000537367142, createdTime=Mon Aug 16 13:16:44 CST 2021, time=2021-08-16, status=1, ipAttribution=)]

2020-12-12 1245a12em04(暂无昵称)

攒人品，纯生信，一天秒拒

114 2

展开2条回复

[GetPortalCommentsPageByObjectIdResponse(id=1240305, encodeId=022a1240305ed, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：胃癌;生信;预后标志物 经验分享：8月9号投稿，22号被拒，期间一直是"Editor Assigned"状态，20号写了一份催稿信，不知道是这个原因，还是本身纯生信原因。被拒说不适合，建议转投，但是该杂志有统计和生信相关主编。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=35, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74665434563, createdName=ms2000000713462597, createdTime=Mon Aug 22 16:56:30 CST 2022, time=2022-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1224993, encodeId=5aab122499350, content=偏重的研究方向：乳腺癌;内分泌治疗 经验分享：三天了还在new submission，大概要多久啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=27, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=99c56511981, createdName=ms8000000784741196, createdTime=Tue Jun 07 16:45:07 CST 2022, time=2022-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1225234, encodeId=59e01225234bb, content=请问大家，投出去三个多月了，反复的“指派审稿人”“审稿重”什么意思呀？已经重复三次了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=29, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c5a35503965, createdName=ms1000001119710084, createdTime=Wed Jun 08 17:31:53 CST 2022, time=2022-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1204339, encodeId=6bb0120433935, content=请问下大家这个杂志格式要求很严格吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=31, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=44935423762, createdName=ms4000001175598795, createdTime=Sun Mar 20 14:01:28 CST 2022, time=2022-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1101376, encodeId=cba911013e68e, content=模式图一般放在讨论中展示还是放在结果部分？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=47, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/3a52d3952dde49019f1e000bb5c41d1c/0a0eb7959bb14fcd87745f869bee3c33.jpg, createdBy=46f32239729, createdName=Mia, createdTime=Wed Dec 29 14:52:51 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1101375, encodeId=a3c311013e5eb, content=讨论中第一段一定要撰写文章的总括么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=47, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ff65466529, createdName=ms6000000264964247, createdTime=Tue Dec 28 14:52:51 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1071356, encodeId=77ad10e135610, content=投了之后说给介绍期刊转投，1周了没有消息，请问有遇到这种情况的同学吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=45, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=02925649921, createdName=ms9000001676514510, createdTime=Thu Nov 18 11:02:32 CST 2021, time=2021-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=522379, encodeId=c5d95223e918, content=刚投一篇回顾性临床研究文章，希望能被接收，祈祷！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=322, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2acf1721622, createdName=1dec8fb5m12(暂无匿称), createdTime=Sat May 14 11:06:00 CST 2016, time=2016-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=907209, encodeId=979390e2098c, content=攒人品，纯生信，一天秒拒, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=114, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0cfd2480964, createdName=1245a12em04(暂无昵称), createdTime=Sat Dec 12 00:13:53 CST 2020, time=2020-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1008310, encodeId=9cd410083104d, content=偏重的研究方向：肿瘤 经验分享：一天秒拒无理由, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=58, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f9015376971, createdName=ms9000000537367142, createdTime=Mon Aug 16 13:16:44 CST 2021, time=2021-08-16, status=1, ipAttribution=)]

2021-08-16 ms9000000537367142

偏重的研究方向：肿瘤
经验分享：一天秒拒无理由

58 1

展开1条回复

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

期刊讨论

科室

工具

服务